3R Inc.

Reports from F. Jacques and co-researchers add new data to research in tacrolimus therapy.
Biotech Week; 12/23/2009; 957 words; ...months; P = .016 at 1 year). Among type 3R ARE, the CsA group showed 0.11...The freedom rate from 1R, 2R, and 3R ARE was therefore similar between the two...Transplantation Proceedings is: Elsevier Science Inc., 360 Park Avenue South, New York, NY...

Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia CML at the 51st Annual Meeting of the American Society of Hematology ASH.
Blood Weekly; 12/17/2009; 675 words; ...Stemline Therapeutics, Inc. announced that data from...clinical studies of its IL-3R targeting agents, SL...Stemline Therapeutics, Inc.). The data demonstrate...activity of these IL-3R targeting agents against...Stemline Therapeutics Inc. This article was prepared...

Publication No. WO/2009/149392 Published on Dec. 10, Assigned to Hollis-Eden Pharmaceuticals for Steroid, Compound Preparation Method (American Inventors)
US Fed News Service, Including US State News; 12/14/2009; 394 words; ...The patent has been assigned to Hollis-Eden Pharmaceuticals Inc., City, United States Of America. According to an abstract...17-hexadecahydro-1 H-cyclopenta[a]phenanthrene- 3R,7R,17S-triol, that are essentially free of process impurities...

Research results from Astellas Pharma, Inc. update knowledge of astellas pharma inc.
Biotech Week; 12/9/2009; 759 words; ...report (see also Astellas Pharma Inc.). "Radioluminograms of the...mainly 6,7-dimethoxy-2-[(3R)-piperidin-3-ylcarbonyl...colleagues, Astellas Pharma, Inc. The researchers concluded...K. Umehara, Astellas Pharma Inc., Drug Discovery Research...

Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH).
PR Newswire; 12/4/2009; 704 words; ...PRNewswire/ -- Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL...About Stemline Therapeutics, Inc. Stemline Therapeutics, Inc. is a...